Table 2.
The occurrence of adverse reactions in immune stage.
| Analysis Item | Zagreb group (N=599) |
Essen group (N=600) |
P value | ||
|---|---|---|---|---|---|
| n | (%) | n | (%) | ||
| Total Adverse Events | 306 | 51.09 | 302 | 50.33 | 0.817 |
| 30min | 36 | 6.01 | 40 | 6.67 | 0.722 |
| D0-D3 | 277 | 46.24 | 275 | 45.83 | 0.908 |
| D0-D7 | 295 | 49.25 | 283 | 47.17 | 0.488 |
| D8-D30 | 42 | 7.01 | 35 | 5.83 | 0.413 |
| Dose 1 | 254 | 42.40 | 190 | 31.67 | 0.001 |
| Dose 2 | / | / | 124 | 21.05 | / |
| Dose 3 | 125 | 21.11 | 95 | 16.24 | 0.036 |
| Dose 4 | 83 | 14.07 | 77 | 13.23 | 0.734 |
| Dose 5 | / | / | 68 | 11.79 | / |
| Adverse Reaction | 272 | 45.41 | 255 | 42.50 | 0.323 |
| 30min | 36 | 6.01 | 40 | 6.67 | 0.722 |
| D0-D3 | 263 | 43.91 | 251 | 41.83 | 0.484 |
| D0-D7 | 272 | 45.41 | 255 | 42.50 | 0.323 |
| D8-D30 | 0 | 0.00 | 0 | 0.00 | 1.000 |
| Dose 1 | 237 | 39.57 | 177 | 29.50 | 0.001 |
| Dose 2 | / | / | 115 | 19.52 | / |
| Dose 3 | 100 | 16.89 | 77 | 13.16 | 0.087 |
| Dose 4 | 52 | 8.81 | 58 | 9.97 | 0.548 |
| Dose 5 | / | / | 37 | 6.41 | / |